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The  use  of  loop  diuretics  has been  shown  to deteriorate  renal  dysfunction  and  is associated  with  a poor
prognosis  in patients  with  heart  failure  (HF).  Tolvaptan,  a vasopressin  V2-receptor  antagonist,  has  been
reported  to be effective  in  treating  HF due  to  its  potent  effects  of  water  diuresis  and  is  expected  to
improve  ﬂuid  retention  without  adversely  affecting  renal  function.  The  present  case  is a 77-year-old  man
with  pulmonary  hypertension  associated  with  chronic  pulmonary  artery  thrombosis  and  old pulmonaryiuretics
eart failure
ulmonary hypertension
enal  dysfunction
olvaptan
tuberculosis  who  developed  worsening  right-sided  HF  with  marked  ﬂuid  retention  and  renal  dysfunction.
In  this  case,  tolvaptan  was  effective  in  improving  HF without  deteriorating  the  patient’s  renal  dysfunction.
<Learning  objective:  Tolvaptan  is effective  in treating  patients  with  right-sided  heart  failure  associated
with  marked  ﬂuid  retention  and  renal  dysfunction  who  are  refractory  to loop  diuretics  and  can  improve
and  control  heart  failure  symptoms  without  worsening  renal  dysfunction.>
©  2014  Japanese  College  of  Cardiology.  Published  by Elsevier  Ltd.  All  rights  reserved.ntroduction
Although loop diuretic drugs, such as furosemide, are commonly
sed to treat patients with heart failure (HF), the use of diuretics
as been shown to deteriorate renal dysfunction and is associated
ith a poor prognosis in patients with HF [1–4]. Tolvaptan, an
ral vasopressin V2-receptor antagonist, has been reported to be
ffective in treating HF due to its potent effect of water diuresis
5,6] and is expected to improve ﬂuid retention without adversely
ffecting renal function [4,7]. The present case involved a patient
ith right-sided HF associated with marked ﬂuid retention and
enal dysfunction refractory to loop diuretics in whom tolvaptan
as effective in improving HF without deteriorating renal dysfunc-
ion. Informed consent for this publication was obtained from the
atient.∗ Corresponding author at: Department of Cardiology, National Hospital Orga-
ization  Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo 152-8902
apan.  Tel.: +81 03 3411 0111; fax: +81 03 3412 9811.
E-mail addresses: ymomiyamajp@yahoo.co.jp,
momiyamajp@gmail.com (Y. Momiyama).
ttp://dx.doi.org/10.1016/j.jccase.2014.02.003
878-5409/© 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reCase report
The  present case was  a 77-year-old man  who had been on
oxygen treatment (O2 1 L/min) for chronic respiratory failure and
pulmonary hypertension due to old pulmonary tuberculosis since
he was 65 years of age. Because the estimated pulmonary artery
systolic pressure was  >50 mmHg  on an echocardiogram, pulmonary
enhanced computed tomography (CT) was  performed at 69 years
of age. As shown in Fig. 1, CT showed defects in both right and
left pulmonary arteries, suggestive of pulmonary artery thrombo-
sis. Although pulmonary artery catheterization was not performed
to conﬁrm pulmonary hypertension, he was considered to have pul-
monary hypertension due to chronic pulmonary artery thrombosis
and pulmonary tuberculosis and then started to take oral anti-
coagulant therapy. At 72 years of age, he underwent permanent
pacemaker implantation for sick sinus syndrome and paroxysmal
atrial tachycardia. For right-sided HF and pulmonary hypertension,
he had been taking 240 mg/day of furosemide and 120 g/day of
beraprost. He also had renal dysfunction, and serum blood urea
nitrogen (BUN) and creatinine (Cre) levels were 38 mg/dL and
1.7 mg/dL, respectively, 1 month before admission. Ten days before
admission, he had developed a cold. He subsequently visited our
outpatient clinic and was admitted to the hospital, with chief com-
plaints of marked leg edema and worsening of shortness of breath.
served.
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aFig. 1. Pulmonary enhanced computed tomography showing defects (arrows) i
 chest X-ray revealed bilateral pleural effusion and cardiac
nlargement with a cardiac thoracic ratio of 71% (Fig. 2); however,
o changes were observed in the electrocardiographic ﬁndings of
entricular pacing with a heart rate of 65 bpm.
On  admission, the patient’s body height was 157.8 cm,  while
is body weight was found to have increased from 42 kg to 50 kg
+8 kg) over the previous 10 days. His blood pressure (BP) was
7/55 mmHg, with a pulse rate of 65 min−1. Marked leg edema and
ugular venous distension were observed. An S3 heart sound and
rade 3/6 left parasternal systolic murmur of tricuspid regurgita-
ion were auscultated. In addition, bibasilar crackles were heard
n the lungs. An echocardiogram showed pulmonary hypertension
ith right ventricular (RV) dilatation and systolic ﬂattening of
nterventricular septum. The pulmonary artery systolic pressure
as estimated to be 53 mmHg  based on the tricuspid regurtitant
et (3.3 m/s) (Fig. 3). However, the left ventricular (LV) systolic
unction was normal. The laboratory data were as follows: pro-
hrombin time (PT) 82.4 s; PT-international normalized ratio
.94; aspartate aminotransferase 73 U/L; alanine aminotrans-
erase 135 U/L; lactate dehydrogenase 323 U/L; rGTP [-glutamyl
ranspeptidase] 50 U/L; BUN 63.7 mg/dL; Cre 2.50 mg/dL; Na
ig. 2. (A) A chest X-ray obtained 3 months before admission showing old pulmonary tu
dmission showing bilateral pleural effusion and cardiac enlargement with a CTR of 71%. right and left pulmonary arteries, suggestive of pulmonary artery thrombosis.
133  mEq/L; K 3.7 mEq/L; Cl 96 mEq/L; brain natriuretic pep-
tide 1781 pg/mL. The patient was  diagnosed to have worsening
right-sided HF associated with pulmonary hypertension and
marked ﬂuid retention. The HF was refractory to the intravenous
administration of 500 mg/day of furosemide; however, 15 mg/day
of tolvaptan with the intravenous administration of dopamine
(3 g/kg/min) was  strikingly effective in treating the HF, resulting
in an increased urine output and decreased body weight (Fig. 4).
The patient’s renal dysfunction also improved in association with
a decrease in Cre level from 3.08 mg/dL to 1.35 mg/dL. On day
20 after admission, an echocardiogram showed the decreased
diameter of inferior vena cava from 23 mm to 17 mm.  However,
the estimated pulmonary artery systolic pressure was  still high
(59 mmHg) based on tricuspid regurtitant jet (3.5 m/s) (Fig. 3). He
was discharged from our hospital with a body weight of 41 kg on
7.5 mg/day of tolvaptan and a decreased dose of 160 mg/day of
furosemide. One month after discharge, the patient stopped taking
tolvaptan daily and was instructed to take 7.5 mg  of tolvaptan only
when his body weight was  more than 42 kg. As a result, he took a
dose of 7.5 mg  of tolvaptan several times per month, and the HF
continues to be well controlled with 160 mg/day of furosemide.
berculosis and a cardiac thoracic ratio (CTR) of 55%. (B) A chest X-ray obtained on
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Fig. 3. (A) Two-dimensional echocardiography (parasternal short-axis view) showing right ventricular dilatation and systolic ﬂattening of interventricular septum on
admission (upper) and on day 20 after admission (lower). (B) Subphrenic long-axis views showing inferior vena cava dilatation (23 mm on admission), but the diame-
ter decreased to 17 mm on day 20. (C) Continuous wave Doppler echocardiography of the tricuspid regurtitant jet (3.3 m/s), suggesting the estimated pulmonary artery
systolic pressure of 53 mmHg on admission. However, on day 20, pulmonary artery systolic pressure was  still high (59 mmHg) based on the tricuspid regurtitant jet
(3.5 m/s).
Fig. 4. The patient’s clinical course, including body weight (BW), urine output (mL/day), and serum creatinine level. Heart failure was refractory to the intravenous adminis-
tration of 500 mg/day of furosemide; however, 15 mg/day of tolvaptan with intravenous dopamine (DOA) (3 g/kg/min) was effective, resulting in an increased urine output
and  decreased BW.  The renal dysfunction also improved in association with a decrease in the creatinine level from 3.08 mg/dL to 1.35 mg/dL. The patient was discharged on
7.5  mg/day of tolvaptan with a decreased dose of 160 mg/day of furosemide.
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Loop diuretics have been shown to reduce renal blood ﬂow and
lomerular ﬁltration rate and stimulate the renin–angiotensin–
ldosterone system, thereby worsening renal dysfunction [1–4].
enal dysfunction is associated with a poor prognosis in patients
ith HF [2,3], and more than 30% of patients hospitalized with
F have renal dysfunction [8]. The up-titration of diuretics is usu-
lly necessary when treating patients hospitalized with worsening
F; however, high doses of diuretics deteriorate renal dysfunc-
ion [6]. In contrast, tolvaptan can induce potent water diuresis
ithout decreasing the renal blood ﬂow and glomerular ﬁltra-
ion rate or activating the renin–angiotensin–aldosterone system
4,7–10]. In an experimental model, tolvaptan has been shown to
revent the progression of both LV systolic dysfunction and renal
njury [11]. Recently, oral tolvaptan was reported to be effective
n treating HF associated with renal dysfunction and hypotension
BP < 105 mmHg) and improving HF without worsening renal dys-
unction or adversely affecting BP [8]. Matsue et al. [10] also showed
olvaptan treatment to be associated with the lower incidence of
orsening renal dysfunction in Japanese patients with acute HF at
igh risk for worsening renal dysfunction. As in a previous study
8], the current case of HF and renal dysfunction was refractory
o the intravenous administration of furosemide; however, oral
olvaptan with a small dose of dopamine was strikingly effective
n improving both worsening HF and renal dysfunction and reduc-
ng the daily dose of furosemide. In addition to tolvaptan, a small
ose of dopamine was used to increase renal artery ﬂow.
Symptoms associated with ﬂuid retention, such as leg edema,
re the main complaints in patients with right-sided HF, as in the
urrent case, and removing excess body ﬂuid represents a major
reatment goal of right-sided HF. Loop diuretics induce diuresis
n association with increasing Na excretion and decreasing serum
smolality, which may  lead to intravascular volume loss rather than
xtravascular volume loss. Worsening renal dysfunction during
F treatment had been attributed to hypoperfusion of the kid-
ey for impaired cardiac output or intravascular volume loss due
o overzealous use of diuretics. However, venous congestion has
ecome recognized as the most important hemodynamic factor
riving worsening renal dysfunction [12]. In patients with right-
ided HF and marked volume retention, worsening renal dysfunc-
ion would be associated with venous congestion and be prevented
y immediate removal of excess body ﬂuid with tolvaptan. Tolvap-
an induces potent water diuresis without increasing Na excretion
r decreasing serum osmolality, thereby effectively ameliorating
uid retention symptoms, such as marked leg edema [7,9]. In previ-
us studies, which reported the efﬁcacy of tolvaptan [5,6], most HF
atients had left-sided HF due to LV systolic dysfunction, while only
5% of patients had right-sided HF. However, as in the present case,
ral tolvaptan was effective in treating the signs and symptoms of
arked ﬂuid retention associated with right-sided HF without LV
ystolic dysfunction and in preventing worsening renal dysfunction
y immediate removal of excess body ﬂuid. After tolvaptan treat-
ent, the inferior vena cava dilatation decreased from 23 mm to
7 mm,  but the estimated pulmonary systolic artery pressure was
till high (59 mmHg). To improve pulmonary hypertension, medical
reatment, such as bosentan and sildenaﬁl, or percutaneous trans-
uminal pulmonary angioplasty may  be needed for this patient.
Tolvaptan  is still recommended only for short-term use in
apan; however, the EVEREST study [13] reported the safety of
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middle-term use of tolvaptan during a median follow-up of 9.9
months. Our patient was discharged on 7.5 mg/day of tolvaptan
with 160 mg/day of furosemide. However, 1 month after discharge,
he stopped taking tolvaptan daily and switched to 7.5 mg of
tolvaptan only when his body weight exceeded the ideal value.
Although he took a dose of 7.5 mg  of tolvaptan several times per
month, the HF was  well controlled on 160 mg/day of furosemide.
The long-term usage of tolvaptan, as shown in the current case,
may be safe and useful for treating and controlling HF, especially
in patients with renal dysfunction and refractory to loop diuretics.
In conclusion, tolvaptan is effective in treating patients with
right-sided HF associated with marked ﬂuid retention and renal
dysfunction who are refractory to loop diuretics and can improve
and control HF symptoms without worsening renal dysfunction.
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